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ABSTRACT 
Bacterial vaginosis (BV) is the most common vaginal condition found in women of reproductive age. 
The lack of published data on the detection of BV-associated pathogens from urine, a non-invasive 
sample, lends novelty to the present study. This study aimed to detect and quantify Gardnerella 
vaginalis, Prevotella bivia, Atopobium vaginae and Lactobacilllus crispatus from urine, as an 
alternative non-invasive method to vaginal swabs from pregnant women using droplet digital PCR 
(ddPCR). A total of n=100 DNA samples (50 paired urine and swabs) were tested.  The samples were 
stratified as BV negative and positive using the BD MAX Vaginal panel assay (Becton Dickinson). 
Total DNA was extracted from urine (10 ml) and swabs (1 ml) using the PureLink Microbiome Kit 
(ThermoFisher Scientific). The concentration of extracted DNA for urine and swab samples was 
determined using the Nanodrop Spectrophotometer (ThermoScientific). Droplet digital PCR was used 
to determine the absolute quantification of the pathogens using commercially available primer and 
probe sets. G. vaginalis was observed as the most abundant microorganism, followed by A. vaginae and 
P. bivia in the BV positive samples.  When comparing abundance of microorganisms across urine and 
swab, it was shown that there was no significant difference across both sample types in the BV negative 
group. A significant difference in the BV positive group (p=0.004) was only observed for A. vaginae. 
Good correlation between the urine and swab was observed for G. vaginalis (R=0.63, p<0.0001), L. 
crispatus (R=0.71, p<0.0001) and P. bivia (R=0.50, p<0.0001). However, a weak correlation across 
both sample types was observed for A. vaginae (R= 0.21, p=0.001). We observed that urine has the 
potential to serve as an alternative sample collection method to detect BV-associated bacteria. In 
addition, the data generated in this study provides a basis for the development of ddPCR as a diagnostic 
tool for BV. 
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CHAPTER ONE 
1. INTRODUCTION 
Bacterial vaginosis, also known as BV, is a clinical condition which is distinguished by alterations of 
the vaginal microbiota, where the predominant normal lactobacilli species are replaced by diverse 
communities of anaerobic and facultative bacteria (1-3). These bacteria include: Gardnerella vaginalis, 
Atopobium species, Prevotella, Mobiluncus, Mycoplasma and numerous other pathogens (2-6).  
The prevalence of BV in women (both pregnant and non-pregnant population) depends on the clinical 
setting, sociodemographic factors, diagnostic criteria, gestational age, vitamin D deficiency, smoking 
and numerous other factors (3, 7, 8). Within Africa, South Africa has the highest prevalence of BV (1). 
The prevalence of BV in pregnant women ranges from 14% to 21% in Western countries and 13.6–18% 
in Asian countries (9). At baseline, 31.03% of the non-pregnant women were diagnosed as BV positive 
in Durban, South Africa (10). 
The common clinical symptom of BV is the occurrence of an abnormal malodorous vaginal discharge. 
Implications of untreated BV include pelvic inflammatory disease (PID) and increased susceptibility to 
sexually transmitted infections (STIs) and human immunodeficiency virus (HIV) (3, 7). These studies 
have further shown that the prevalence of HIV infection appears to correlate with increasing severity of 
BV (7, 11, 12). Untreated BV is also associated with severe pregnancy outcomes that include late 
miscarriages, preterm labour, premature rapture of membranes (PROM), post-partum endometritis, low 
birth weight infants and a host of other complications (6, 13, 14).   
Bacterial vaginosis is classically diagnosed using the gold standard, Nugent Scoring System (5-7, 14, 
15). Other methods of diagnosis include Amsel Criteria and a host of nucleic acid amplification tests 
(qualitative and quantitative polymerase chain reaction (PCR)) (3, 5, 6, 14).  However, the limitation of 
current diagnostic methods is the use of vaginal swabs. Vaginal swabs are not ideal for use as a 
diagnostic specimen during pregnancy since it is considered to be an invasive method of sample 
collection.  In contrast, urine is a non-invasive sample.   
Recent studies have reported on the use of PCR to diagnose BV, however, these studies have used 
vaginal swabs to detect the BV pathogens using PCR (16-20). In majority of health care clinic settings, 
pregnant women are routinely screened for the presence of glucose and leukocyctes in their urine. As a 
result of urine being collected at every visit, it makes urine easy to be collected for BV testing. The aim 
of this study was to detect and quantify microorganisms associated with BV by droplet digital PCR 
(ddPCR) from urine and vaginal swab samples of pregnant women. This study will be the first to 
provide data on the detection and quantification of BV pathogens from urine collected from South 
African pregnant women.  
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CHAPTER TWO 
2. THE LITERATURE REVIEW 
2.1. Definition of Bacterial Vaginosis  
BV is the most common lower genital tract disorder in women of reproductive age (1). The common 
symptoms of BV include: vaginal pain, itching, abnormal vaginal discharge and/or a burning sensation 
(3). Bacterial vaginosis is defined as a vaginal condition in which the dominant healthy Lactobacilli are 
replaced by a variable mixture of anaerobic and facultative bacteria (2).  The exact composition of the 
bacterial microbiota cannot be identified in woman as it varies from each women, however, the common 
BV-associated pathogens include Gardnerella, Atopobium, Prevotella, Megasphaera, Sneathia and 
Mycoplasma (2-6).  
2.2. Epidemiology of BV 
The aetiology of BV and the reason for the differing prevalence across the world is unclear. In a 
systematic review by Kenyon et al 2013 (1), the global epidemiology of BV was attempted to be 
summarized using the data from peer-reviewed publications that used the Nugent scoring criteria to 
diagnose the patient with BV. In Sub-Saharan Africa, BV prevalence was the highest in the Southern 
and Eastern parts of Africa. In Africa, South Africa had the highest prevalence of BV. The prevalence 
of BV in Durban was 52% and in rural KwaZulu-Natal and Khayelitshia the prevalence of BV was 
around 58% (1).  Gambia had the second highest prevalence of BV at 37% followed by Uganda at 34%. 
The lowest prevalence of BV was 12% in Maputo, Mozambique (1). During pregnancy, the reported 
prevalence of BV, ranges from 4.9% to 49% (9). The prevalence of BV in women (both pregnant and 
non-pregnant population) depends on the clinical setting, sociodemographic factors, diagnostic criteria, 
gestational age and numerous other factors (8). The prevalence of BV in pregnant women ranges from 
14% to 21% in Western countries and 13.6–18% in Asian countries (9). In South Africa, the prevalence 
of BV was reported to be 17.6% in a population of pregnant women (21). 
2.3. Risk factors for BV 
There are numerous risk factors that are associated with BV. Many of these factors fall under the 
lifestyle category. Sexual activity plays a major contributory role in BV. The lack of condom use, 
multiple sexual partners or new sexual partners can result in BV acquisition. Sexual intercourse alters 
the normal vaginal microbiome and introduces new vaginal microorganisms. Other reported risk factors 
include intrauterine devices, black ethnicity, vaginal douching; smoking, lack of male circumcision, 
poverty, poor education, low vitamin D levels and genetic variation of a wide range of host genes (3, 7, 
22) 
2.4. Consequences of BV in pregnant women 
Bacterial vaginosis is a lower vaginal tract condition that causes numerous problems pre and post 
pregnancy. In pregnancy, BV can result in late miscarriages, preterm labour, premature rupture of 
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membranes (PROM), post-partum endometritis, low birth weight infants and a host of other 
complications (6, 13, 14). BV is also associated with the increased risk of acquisition of human 
immunodeficiency virus (HIV) and sexually transmitted infections (STIs)  such as gonorrhoea, 
trichomoniasis and herpes simplex virus type 2 (7). Several studies show that women with BV have a 
higher incidence of HIV infection. The prevalence of HIV infection also correlates with increasing 
severity of BV (3, 7, 11, 12). 
2.5 Microorganisms associated with BV 
As mentioned earlier, the common BV-associated pathogens include Gardnerella, Atopobium, 
Prevotella, Megasphaera, Sneathia and Mycoplasma (2-6). Some of these microorganisms are 
described in greater detail below:  
2.5.1. Gardnerella Vaginalis 
2.5.1.1. Morphological characterization  
In 1953, Gardnerella vaginalis (G. vaginalis), was first isolated by Dr. S. Leopold (23). G. vaginalis 
belongs to the family bifidobacteriaceae (3). G. vaginalis has cells which are small, non-motile, non-
encapsulated, non-spore-forming, pleomorphic rods and has an average dimension of 0.4 by 1.5 µm. 
When Gram-stained, the cells appear as Gram variable as a result of its peptidoglycan layer (Fig 1a). 
G. vaginalis, is a fastidious microorganism and requires the presence of carbon dioxide for growth (24).  
 
 
Fig. 1 (a) displays the Gram stain of G. vaginalis. It appears to be Gram variable and pleomorphic 
rods are observed. (b) Displays a clue cell. Clue cells are the clustering and adherence of G. 
vaginalis on the vaginal epithelial cell (25).  
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2.5.1.2. Role in BV 
Gardnerella has been one of the most consistent microorganisms associated with BV. It has been 
reported that vaginal mucosa polymicrobial biofilms are associated with BV (3, 4, 26). Gardnerella 
adheres to the vaginal epithelial cells (known as a clue cell) and forms a biofilm on the walls of the 
vagina (Fig. 1b). This mechanism permits the tolerance of Gardnerella to lactic acid and hydrogen 
peroxide which are produced by lactobacilli. G. vaginalis can also be found in a healthy vaginal 
microbiome (in lower concentrations), thereby suggesting that G. vaginalis does not always form a 
biofilm. Researchers have hypothesized that different G. vaginalis strains may contain different 
virulence potentials (4). Recently, a comparative analysis of 17 clinical isolates of G. vaginalis 
suggested that the species can be subdivided into 4 clades and that there may be multiple species of G. 
vaginalis. Ahmed et al found that the degree of diversity among the strains was exceptionally high for 
a single species (27). 
2.5.2. Atopobium vaginae 
2.5.2.1. Morphological characterization 
Atopobium vaginae (A. vaginae) was first associated with bacterial vaginosis in 2004 (28). However, 
Atopobium was discovered in 1999 by Rodriguez as a common commensal of the woman’s vagina (29). 
A. vaginae belong to the family Coriobacteriaceae and are represented by anaerobic, small, elongated, 
Gram positive cocci bacteria (3). A. vaginae are cocci that appear singly, in pairs or in short chains (Fig. 
2). Atopobium is not used as one of the key microorganisms in the Nugent scoring system, as the 
variable cells can be camouflaged and overlooked during microscopic examination. This 
microorganism is a fastidious bacterium and grows slowly in agar media thereby making it difficult to 
culture (3).   
 
 
 
 
 
 
 
 
Fig. 2 Micrograph of a Gram stain showing Gram-positive bacteria, with A. vaginae visible as 
single cells, in pairs or short chains (30). 
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2.5.2.2. Role in BV 
Atopobium has only been reported about 10 years ago to be involved in BV. Swidsinski et al (2013) 
found vaginal biopsies with vaginal biofilm to be positive for G. vaginalis and A. vaginae when using 
fluorescent probes (31). Gardnerella is capable of adhering strongly to the vaginal epithelial cells and 
forms vaginal biofilms. G. vaginalis initiates the colonization of the vaginal epithelium and creates the 
environment for other BV-associated pathogens to attach, an example is A. vaginae. Molecular studies 
demonstrated that the probable role of Atopobium in BV could be in the establishment of the biofilm 
together with G. vaginalis. A. vaginae has been reported to be found in 80-90% of relapse cases of BV 
(32). Therefore, A. vaginae is considered one of the important microorganisms associated with BV. 
However, whether A. vaginae plays a more central role in the pathogenesis of BV has not been 
established (3). A study conducted by Bradshaw et al (2006) reported that A. vaginae is strongly 
associated with recurrent BV and that it is rarely detected without G. vaginalis (33, 34). 
2.5.3. Prevotella species 
2.5.3.1. Morphological characterization 
Prevotella species belong to the family Prevotellaceae. These bacteria are anaerobic, Gram negative, 
pleomorphic, non-motile rods that were previously classified as Bacteriodes (3). Studies have shown 
that Prevotella make up the “Bacteriodes morphotype” which is used to determine Nugent scores and 
that species of the genus Bacteriodes are rare. In comparison to other species of Prevotella, Prevotella 
bivia is considered to be significantly associated with BV (3).  
2.5.3.2. Role in BV 
Prevotella species produce polyamines during metabolic activity which increase the vaginal pH. The 
increase in vaginal pH enhances the growth for other anaerobic BV-associated pathogens. The 
production of ammonia by this bacteria was shown to enhance the growth of G. vaginalis. A synergistic 
relationship exists between both G. vaginalis and Prevotella as the amino acid produced by G. vaginalis 
is utilized by Prevotella. Therefore, Prevotella species have a positive association with bacterial 
vaginosis (3).  
2.6. Microorganisms associated with a healthy vagina 
2.6.1. Lactobacillus species 
2.6.1.1. Morphological characterization 
Lactobacillus species belong to the family Lactobacillaceae. Lactobacillus are Gram positive, 
facultative anaerobic, rod shaped and non-spore forming bacteria (Fig. 3). In around 70% of women, a 
Lactobacillus species is dominant, although that has been found to vary between American women of 
European origin and those of African origin, the latter group tending to have more diverse vaginal 
microbiota. Similar differences have also been identified in comparisons between Belgian and 
Tanzanian women (35). There are four major types of Lactobacillus species that play a role in BV: 
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Lactobacillus crispatus, Lactobacillus iners, Lactobacillus gasseri, or Lactobacillus jensenii. 
Lactobacillus crispatus (L. crispatus) is reported to be the most dominant of the four species to be found 
in a healthy vaginal microbiome (36). Lactobacillus gasseri, and Lactobacillus jensenii also play a role 
in keeping the vaginal environment healthy and free from pathogens. However, it has been reported that 
a Lactobacillus iners (L. iners) dominated vaginal community seems to be less stable than the other 
species and is more frequently associated with vaginal dysbiosis (Fig. 4). L. iners is reported to be a 
transitional bacteria since it can be found in the healthy vaginal microbiome as well as in a non-healthy 
vaginal microbiome (i.e. BV positive patient) (37) 
L. cripatus, is the dominant component in the healthy vaginal microbiota in women all across the world. 
Lactobacillus maintains a healthy vagina as it produces a substantial amount of lactic acid and hydrogen 
peroxide that sustains an acidic vaginal environment of a pH of 3.5-4.5. A maintained acidic 
environment inhibits the overgrowth of pathogenic microorganisms such as the BV causing bacteria 
(G. vaginalis, A. vaginae etc.) (2, 36, 37).  
 
 
Fig. 3: Depicts large Gram positive rod shaped Lactobacillus species (25).  
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Fig. 4 Schematic diagram illustrating the different species of Lactobacilli and the role they play 
in the vaginal microbiota. L. crispatus, L. gasseri and L. jensenii maintain the healthy vaginal state 
whilst L. iners is a transitional bacteria. L. iners can be found in both the healthy and non-healthy 
vaginal microbiota (37). 
2.7. Diagnosis of BV: Non-molecular biology based methods  
The clinical diagnosis of BV is identified by the presence of at least three out of the four Amsel criteria 
which include: a raised vaginal pH (above 4.5), an increased amount of vaginal discharge (milky in 
colour), the presence of clue cells when vaginal fluid smears are examined by a microscope and an 
amine odour after 10% potassium hydroxide has been added (3, 5, 38). The advantages of the Amsel 
criteria are as follows: method of detection does not require intensive training; it is cost effective as 
well as easy and fast to perform. However, this method is not considered ideal for BV diagnosis due to 
its low specificity (5).  
An alternative clinical diagnosis for the detection of BV is Gram staining of vaginal smears. This 
method is evaluated according to the Nugent scoring system ("gold standard"). This system scores 
vaginal smears from 0 to 10, depending upon the numbers of three bacterial morphotypes which are 
seen on the slide that contains the smear. These bacteria include Gardnerella vaginalis/Bacteriodes, 
Mobiluncus and Lactobacilli (3, 5, 6, 15). A score of 0–3 represents normal vaginal microbiota (BV 
negative), a score of 4–6 represents intermediate vaginal microbiota, and a score of 7–10 is considered 
as diagnostic for BV (BV positive) (7, 15). Although this method of detection is fast and easy to 
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perform, it has the following disadvantages:  the vaginal smears used remain subjective, this method is 
user dependent and it requires a trained laboratory personnel to prepare and read the slides.  Thus, it is 
not a suitable choice of method to be implemented in primary health care facilities.  
2.8. Diagnosis of BV: Molecular Biology based methods  
The main microorganisms associated with BV are obligate anaerobes that are either difficult to recover 
or unrecoverable using culture-based methods. This makes the true evaluation of the vaginal 
microbiome using microbial culture methods challenging. The knowledge on the microbial ecosystem 
of BV and the association of different bacteria with BV, has increased due to advances in molecular 
techniques. These molecular techniques include: conventional PCR, real-time PCR, multiplex PCR, 
broad-range bacterial 16s rDNA PCR, and fluorescence in situ hybridization (FISH) (3, 6). 
 Polymerase Chain Reaction assays of vaginal-fluid samples provides information on the bacterial 
compositions in the female vagina from women with and without BV. Development of PCR-based 
assays can be used to detect and quantify genital tract organisms (e.g. mycoplasmas cannot be detected 
using Gram stain). This is useful since Mycoplasma hominis is suggested to be associated with BV and 
cannot be identified using microbial culture methods. As per the BD MAX assay which is an FDA 
approved multiplex PCR assay for the quantitative detection of BV, the following microorganisms form 
part of the panel: Lactobacillus crispatus and Lactobacillus jensenii (LoD: 510 cfu/ml), Gardnerella 
vaginalis (LoD: 962 cfu/ml), Atopobium vaginae (LoD: 127 cfu/ml), BV associated bacteria-2 (LoD: 
464 copies/ml) and Megasphaera-1. A study done by Dhiman et al 2016  (39), showed that PCR has a 
higher sensitivity for the diagnosis of BV when compared to Nugent scoring. The predisposition of 
specific bacteria towards the development of BV or the pathological outcomes of BV can be determined 
using PCR. PCR-based assays offers the ability to be less subjective when diagnosing BV as compared 
to alternative methods.  This is because PCR assays can be developed  to provide quantitative analysis 
(copy number) for specific types of organisms in the genital tract (3, 14).  
2.9. Droplet Digital Polymerase Chain Reaction 
2.9.1 What is ddPCR? 
Droplet digital PCR is an advanced quantitative PCR assay that relies on water-oil emulsion droplet 
technology. It is an ultrasensitive technology that provides absolute nucleic acid quantification (40, 41).  
2.9.2 The process of ddPCR 
Figure 5 shows the schematic workflow of ddPCR. As shown in figure 5, the sample and the test 
reagents are loaded into the eight channel droplet generator cartridge.  Thereafter, a vacuum is applied 
to draw the sample and oil.  In approximately 2 minutes the eight samples are converted into eight sets 
of 20 000 droplets. The surfactant-stabilized droplets are transferred to a 96-well PCR plate. The plate 
is then inserted into a conventional thermocycler for droplet PCR amplification. The droplets are 
assigned colours to indicate if they are negative or positive which is based on their fluorescence 
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amplitude (40-42). Each droplet in a sample is plotted on a graph of fluorescence intensity versus droplet 
number. All positive droplet are scored as positive (above threshold intensity) and each is assigned a 
value of 1. All negative droplets (below the threshold) are scored as negative and assigned a value of 
zero. This counting technique provides a digital signal from which to calculate the starting targeting 
DNA concentration by a statistical analysis of the numbers of positive and negative droplets in a given 
sample. ddPCR from a multiplex experiment in which two targets are PCR amplified can also be viewed 
as a 2 dimensional plot in which FAM fluorescence is plotted versus HEX fluorescence for each droplet.  
 
Fig. 5: Schematic representation of the workflow of droplet digital PCR (42). 
2.9.3. Application of ddPCR 
The application for ddPCR covers various areas of biology. The first application that ddPCR is used for 
is liquid biopsy. Liquid biopsy is a non-invasive test that detects cancer cells from DNA which is shed 
from tumours in the blood. Target circulating tumour DNA are present at low levels in a complex 
background of cell-free DNA. The high level of sensitivity permits ddPCR to accurately detect and 
quantify rare sequences in the presence of abundant targets. The second application in which ddPCR is 
used is for copy number variation (CNV). Over 10% of the human genome is composed of CNVs that 
contain sequences larger than 1 kb. Droplet digital PCR has been demonstrated to be well suited for 
high-throughput studies that profile CNV (43). Droplet digital PCR can provide accurate CNV 
quantification in single wells. The precision and sensitivity of ddPCR technology allows the system to 
distinguish small changes much more readily. Furthermore, the accuracy of ddPCR is less sensitive to 
changes in amplification efficiency, consequently creating large inaccuracies in qPCR measurements. 
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A third application for the use of ddPCR is gene expression. The precision of ddPCR provides higher 
resolution in gene expression measurements. Droplet digital PCR allows scientists to accurately and 
precisely quantify the finer changes in expression levels less than twofold. Droplet digital PCR can also 
be used to increase the accuracy and efficiency of next generation sequencing (44). A final application 
that ddPCR can be used for is the microbiome analysis and pathogen detection. This is currently the 
most widespread use of ddPCR in microbiology. The analysis of microbiome and pathogen detection 
requires the detection and quantitation of low-abundance microorganisms in a complex background.  
Droplet digital PCR is used in pathogen detection for detecting and monitoring viral loads, microbial 
drug resistance as well as for the detection of pathogens in food (44).  
2.9.4. Advantages and disadvantages of using ddPCR 
When compared to qPCR, ddPCR has the following advantages: absolute quantification without the 
need for a standard curve, less affected by sample inhibitors, not affected by poor amplification 
efficiency, provides more precision and improved detection of low-copy number variants (44). Droplet 
digital PCR reduces the overall cost, uses lower sample and reagent volumes when compared to other 
molecular methods whilst still maintaining the overall sensitivity and precision. Several other benefits 
of using ddPCR include: absolute quantification (provides an absolute count of target DNA copies per 
input sample) without the need of generating a standard curve, lower equipment cost as well as reduced 
consumable costs.  Other benefits of ddPCR include: High throughput (simple and easy to use workflow 
with 96 sample throughput  which does not require multiple dilution steps) and it also eliminates PCR 
efficiency bias (error rates are reduced by removing the reliance on amplification efficiency of qPCR) 
(42).  
Despite the several advantages outlined above, ddPCR may also be accompanied with some 
disadvantages that include: limited reaction mixture volume, smaller dynamic range, molecular dropout, 
less accurate quantification of larger amplicons and lower throughput when compared to qPCR. 
2.10. Current study: Rationale, aims and objectives 
2.10.1. Study Rationale  
Currently, there is a lack of published data on the diagnosis of BV from urine samples of pregnant 
women in our setting, thereby making this study novel. The detection of BV-associated pathogens from 
urine offers a much more comfortable, convenient and less biased sampling method when compared to 
vaginal swabs (downstream processing is dependent on amount of material on swab) especially for 
pregnant women. In majority of the health care clinic settings, pregnant women are screened for glucose 
and leukocyctes in urine (45). Therefore, it makes urine easy to be collected for BV testing.  In addition, 
there is also limited information on the use of ddPCR for absolute quantification of BV-associated 
microorganisms. The data generated from this study will add to the growing body of literature regarding 
the methods of diagnosis for BV. If urine is found to be a feasible sample for diagnosis of BV, this 
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could inform the development of newer testing platforms for this syndrome which could lead to the 
development of ddPCR using urine as a diagnostic test for BV.  
2.10.2. Aims of the study  
The aim of this study is to detect and quantify microorganisms associated with bacterial vaginosis by 
droplet digital PCR from urine and vaginal swab samples of pregnant women. 
2.10.3. Study Objectives  
The first objective of this study was to select paired urine and swab samples from pregnant women who 
were diagnosed as BV positive and BV negative. The second objective was to extract DNA from urine 
and swabs using a commercially available kit. The third objective was to detect and quantify 
Gardnerella vaginalis, Atopobium vaginae, Prevotella bivia (pathogenic bacterium) and Lactobacillus 
crispatus (normal vaginal microbiota) from the paired DNA samples by droplet digital PCR. These 
microorganisms were selected since they are strongly associated with BV.  The fourth objective was to 
compare the abundance of each BV pathogen in the urine and swab samples. Lastly, the final objective 
was to rank the abundance of each BV pathogen. 
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CHAPTER THREE 
3. MATERIALS AND METHODS 
3.1 Ethical statement  
Full ethics approval for the present study was granted by the Biomedical Research Ethics Committee 
(BREC) of the University of KwaZulu-Natal (BE276/18) (Appendix 2). 
3.2 Study setting and population 
This study is a sub-study of a larger study. For the larger study, pregnant women 18 years and older, 
willing to provide written informed consent, willing to provide biological samples and willing to be 
tested for vaginal pathogens were recruited from the King Edward VIII hospital in Durban, South Africa 
between November 2017 and April 2018 (Appendix 2). Data on socio-demographic, behavioral and 
clinical information was collected from the study participants using a structured questionnaire.  Each 
woman provided a self-collected vaginal swab and urine sample. The vaginal swabs were collected 
before the urine sample. The vaginal swabs were eluted in 10% phosphate buffered saline (PBS) and 
the recovered suspension was stored at -20˚C until further use. Urine samples were subjected to DNA 
extraction on the day of collection and the recovered DNA was stored at -20˚C until further use. The 
BV status of the enrolled women was determined using the BD MAX Vaginal Panel assay (Becton 
Dickinson) on the self-collected swabs. This assay is an FDA approved assay which incorporates 
automated DNA extraction and real-time polymerase chain reaction (PCR) for the direct, qualitative 
detection of pathogens from DNA of vaginal specimens. Results are qualitative and are reported as a 
result for  Bacterial Vaginosis {by using an algorithm that calculates the ratio of Lactobacillus crispatus 
(LoD: 55cfu/ml) and Lactobacillus jensenii (LoD: 510 cfu/ml), Gardnerella vaginalis (LoD: 962 
cfu/ml), Atopobium vaginae (LoD: 127 cfu/ml), BV associated bacteria-2 (LoD: 464 copies/ml) and 
Megasphaera-1 (LoD: 2265 copies/ml)}.We did not use the Nugent scoring since we found that this 
technique did not work with self-collected vaginal swabs as collected in this study due to inadequate 
sample material on the majority of the swabs.  
 Women who presented with symptoms of abnormal vaginal discharge were treated as per the 
syndromic management guidelines. The guidelines advocate the use of a 2g single dose of 
metronidazole and clotrimazole vaginal pessary (single dose) or clotrimazole vaginal cream (12 hourly 
for seven days).   
3.3 Sample selection 
For this sub-study, a total of n=50 paired urine and swab DNA samples was used (25 per group). The 
study sample set included n=25 BV negative samples and n=25 BV positive samples for both urine and 
swab.  Women for this sub-study were selected at random according to their BV status (BV negative or 
positive) based on the BD MAX results.   
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3.4 Laboratory testing 
3.4.1. DNA isolation 
Total DNA was extracted from urine (10 ml) and swabs (1 ml) using the PureLink Microbiome Kit 
(ThermoFisher Scientific). The concentration of extracted DNA for urine and swab samples was 
determined using the Nanodrop Spectrophotometer (ThermoScientific). 
3.4.2. Droplet Digital PCR 
Droplet digital PCR is an advanced quantitative PCR assay that relies on water-oil emulsion droplet 
technology, and offers the benefits of minimal sample and reagent volumes when compared to other 
methods, whilst still maintaining the overall sensitivity and precision.  Furthermore, ddPCR determines 
absolute quantification i.e. absolute count of target DNA copies per input sample without the need of 
generating a standard curve (40, 41).  
TaqMan probes (Thermo Fisher) were used to quantify Gardnerella vaginalis (Assay ID: 
Ba04646236_s1), Prevotella bivia (Assay ID: Ba04646278_s1), Atopobium vaginae (Assay ID: 
Ba04646222_s1) and Lactobacillus crispatus (Assay ID: Ba04646245_s1). A total of 2.5µl of extracted 
DNA from either urine or swabs was used in the 20µl ddPCR reaction with the 2x digital PCR supermix 
for probes (No dUTP). Droplets were generated using the manual droplet generator (Bio-Rad), Droplet 
Generation Oil for Probes (Bio-Rad) and the PCR mix containing the sample. A total of 40µl of droplets 
were used for the PCR reaction, with the following conditions; 95℃ for 10 min, 40 cycles of 94℃ for 
30 sec and 60℃ for 1 min, and 98℃ for 10 min. Samples were read on the QX200 Droplet Reader 
(Bio-Rad) using the QuantaSoft Software and acquired on Ch1 for FAM. Analysis was performed on 
the QuantaSoft Software using manual thresholding.  
3.5. Statistical analysis 
The analysis was conducted in two stages, namely the descriptive and inferential statistics. Since the 
data showed some deviation from normality and with some extreme values, the nonparametric tests 
were used to compare any differences in measurements between groups. Wilcoxon tests were used to 
assess the differences between two groups, whereas the Kruskal test applicable to more than two groups. 
The distributions within the groups were also visually displayed as boxplots. All the analysis was done 
with the aid of a freely available Statistical Computing software called R, version 3.6.1. The correlation 
between urine and vaginal swab groups were evaluated using Spearman’s correlation (GraphPad, USA) 
and significance was tested at p< 0.05. 
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CHAPTER FOUR 
4. RESULTS 
4.1 Characteristics of study population  
Table 1 describes the characteristics of the pregnant women investigated in this study. In this population, 
a higher proportion of the women did not experience symptoms of abnormal vaginal discharge at 
enrolment (66% vs 34%). The majority of the women had attained a high school level of education 
(64%) and were unmarried (84%). With respect to sexual behaviour, most women had reported having 
a regular sexual partner (90%), experiencing sexual debut between the ages of 15-20 years (84%), 
having between 2-4 lifetime sexual partners and not practicing condom use during their last sex act 
(46%).  Most women were in the third trimester of pregnancy (56%) and had no previous history of 
STIs (52%). When stratified according to BV status, having a regular sex partner and trimester of 
pregnancy was found to be statistically significant with being BV positive. Women who reported having 
a regular sex partner had a prevalent BV infection when compared to women who did not have a regular 
sex partner (p= 0.05). A higher proportion of women in the third trimester of pregnancy were BV 
positive when compared to women in the first and second trimester of pregnancy (p=0.04). 
Table 1: Characteristics of the study population according to BV status 
 
BV 
Positive 
BV 
Negative 
Total P 
value 
Total 25 25 50 
 
Age 
   
0.602 
mean(SD) 29.2 (5) 28.4 (6.7) 28.8 
(5.9) 
 
Current abnormal discharge  
   
0.136 
No 14 (56) 19 (76) 33 (66) 
 
Yes 11 (44) 6 (24) 17 (34) 
 
Level of education  
   
0.377 
Primary school 1 (4) 0 (0) 1 (2) 
 
High school 14 (56) 18 (72) 32 (64) 
 
College/University 10 (40) 7 (28) 17 (34) 
 
Married  
   
0.702 
No 22 (88) 20 (80) 42 (84) 
 
Yes 3 (12) 5 (20) 8 (16) 
 
Has a regular sex partner 
   
0.05 
No 0 (0) 5 (20) 5 (10) 
 
Yes 25 (100) 20 (80) 45 (90) 
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Cohabiting with partner 
   
0.39 
No 13 (52) 16 (64) 29 (58) 
 
Yes 12 (48) 9 (36) 21 (42) 
 
Age of first sex  
   
0.83 
<15 1 (4) 1 (4) 2 (4) 
 
15-20 22 (88) 20 (80) 42 (84) 
 
21-25 2 (8) 3 (12) 5 (10) 
 
>25 0 (0) 1 (4) 1 (2) 
 
Number of lifetime sex partners  
   
0.816 
1 6 (24) 7 (28) 13 (26) 
 
2-4 11 (44) 12 (48) 23 (46) 
 
>4 8 (32) 6 (24) 14 (28) 
 
Partner has other partners 
   
0.186 
No 5 (20) 9 (36) 14 (28) 
 
Yes 12 (48) 6 (24) 18 (36) 
 
Don’t know 8 (32) 10 (40) 18 (36) 
 
Condom use 
   
0.597 
Never 6 (24) 5 (20) 11 (22) 
 
Rarely 3 (12) 1 (4) 4 (8) 
 
Sometimes 15 (60) 16 (64) 31 (62) 
 
Always 1 (4) 3 (12) 4 (8) 
 
Condom use at last sex act 
   
0.37 
No 15 (60) 18 (72) 33 (66) 
 
Yes 10 (40) 7 (28) 17 (34) 
 
Smokes  
   
1 
No 24 (96) 24 (96) 48 (96) 
 
Yes 1 (4) 1 (4) 2 (4) 
 
Consumes alcohol 
   
0.189 
No 20 (80) 24 (96) 44 (88) 
 
Yes 5 (20) 1 (4) 6 (12) 
 
Intravaginal practices  
   
0.11 
Yes 4 (16) 0 (0) 4 (8) 
 
No 21 (84) 25 (100) 46 (92) 
 
Trimester of pregnancy 
   
0.04 
1st 6 (24) 1 (4) 7 (14) 
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2nd 9 (36) 6 (24) 15 (30) 
 
3rd 10 (40) 18 (72) 28 (56) 
 
Past preterm delivery  
   
0.189 
No 20 (80) 23 (95.8) 43 
(87.8) 
 
Yes 5 (20) 1 (4.2) 6 (12.2) 
 
Past miscarriage 
   
0.48 
No 19 (76) 21 (84) 40 (80) 
 
Yes 6 (24) 4 (16) 10 (20) 
 
Abnormal discharge in the past 
   
0.254 
No 12 (48) 16 (64) 28 (56) 
 
Yes 13 (52) 9 (36) 22 (44) 
 
Previous treatment of Sexually transmitted 
infections 
   
1 
No 13 (52) 13 (52) 26 (52) 
 
Yes 12 (48) 12 (48) 24 (48) 
 
 
4.2 Quantification of extracted DNA by spectrophotometry  
DNA was successfully extracted from all samples processed. The concentration of urine-extracted DNA 
occurred in the range 1.2 – 585 ng/µl with accompanying A260/A280 ratios in the range 0.32-1.93. The 
swab-extracted DNA concentrations ranged from 2.6-134.6 ng/µl with A260/A280 ratios of 0.88-1.87. All 
patient samples that were tested produced valid results for the ddPCR reactions. The quality controls 
used in the ddPCR runs had produced the desired outputs and ddPCR was also able to detect the 
concentration of the DNA in both the urine and swab samples despite having relatively low A260/A280 
purity ratios (Appendix 1) 
When comparing the median DNA concentration and purity values in the urine versus the swab sample 
samples across BV positive and BV negative samples, it was observed that there was no significant 
difference between both sample types across the BV states (p>0.05) (Table 2, Fig 6). This indicates that 
there was no bias in the sample quality or integrity for the future downstream reactions.  
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Table 2: The ranges of concentration and purity in swab and urine samples DNA 
   Purity  Concentration 
DNA_in status  Q1 Q2 Q3  Q1 Q2 Q3 
swab Negative  1.4625 1.715 1.81  7 12.95 18.95 
swab Positive  1.62 1.72 1.82  7.1 11.8 26.2 
urine Negative  0.7975 1.23 1.5175  4.75 9.65 14.2 
urine Positive  0.42 0.99 1.49  4.9 9.9 15.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6: Comparison of the DNA concentration and purity values in the swab and urine samples 
across the BV states.  
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4.3 Droplet Digital PCR 
All samples produced valid results for the ddPCR reactions. A complete set of raw data for each 
pathogen is represented as Appendix 1. Sample numbers 1-25 were classified as BV negative and 
sample numbers 26-50 were classified as BV positive.  
The ddPCR was able to detect and quantify G. vaginalis across the BV states from urine and swab 
DNA. As expected a higher copy of this bacterium was present in the BV positive samples when 
compared to BV negative samples. Similarly, for A. vaginae and P. bivia higher copy numbers of these 
bacteria were found in BV positive samples when compared to the negative samples.  
According to the ddPCR analysis, L. crispatus was shown to be present in higher abundance in the BV 
negative samples when compared to the BV positive samples (Appendix 1). 
4.3.1. Quantitative comparisons of BV-associated pathogens in urine versus vaginal swab samples 
The median copy numbers of each bacterium quantified from urine was compared to the copy numbers 
of each bacterium for the swab samples. This comparison was made across the BV states. According to 
Fig. 7 for the BV negative samples, there was no significant differences in the median copy number of 
each bacterium between the urine and swab samples (p>0.05).  However, in the BV positive samples a 
higher median copy for A. vaginae was observed in the swab samples when compared to the urine 
samples (p=0.004).  
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Fig. 7: Comparison of the median copy numbers of each bacterium in urine sample when 
compared to the swab sample 
A spearman’s correlation for the swab and urine samples for each pathogen was performed. A good 
correlation between the two sample types was noted for G. vaginalsis, P. bivia and L. crispatus (Fig. 
8). This data is in accordance with Fig. 7 which showed that there is no significant difference in the 
copy numbers across both sample types for the pathogens above. However, for A. vaginae a weak 
correlation between urine and swab samples was noted (Fig. 8). This can be expected, since a significant 
difference in the bacterial abundance between urine and swab samples was observed for A. vaginae in 
the BV positive group (Fig. 7). 
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Fig. 8: The graph shows the correlation of urine versus swab samples for the detection and 
quantification of L. crispatus. A strong correlation between the sample types, R= 0.71, p<0.0001 
was observed. The plot shows the correlation of urine versus swab samples for G. vaginalis. A 
strong correlation between urine and swab samples, R= 0.63, p<0.0001 was observed. The graph 
on the bottom left displays the correlation of urine versus swab samples for P. bivia is shown here. 
A strong correlation between urine and swab samples, R=0.50, p< 0.0001 was observed; followed 
by the correlation of urine versus swab samples for A. vaginae. A weak correlation between urine 
and swab samples, R= 0.21, p=0.001 was observed.   
4.3.2 Comparison of the abundance of each bacterium across the BV states  
For the swab samples, it was observed that a higher copy number of A. vaginae and G. vaginalis was 
present in the BV positive samples when compared to the BV negative samples (p <0.001), respectively 
(Fig. 9). For L. crispatus, a higher copy number of this bacterium was present in the BV negative 
samples when compared to the BV positive samples (p=0.029) (Fig. 9).  
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Similarly, for the urine samples, it was observed that a higher copy number of A. vaginae and G. 
vaginalis was present in the BV positive samples when compared to the BV negative samples (p= 0.041 
and p=0.029), respectively. As observed with the swab samples,  a higher copy number of L. crispatus, 
was present in the BV negative samples when compared to the BV positive samples (p=0.004) (Fig. 9). 
There was no significant association between the copy numbers of P. bivia in both urine and swab 
samples across the BV states (p= 0.321 and p= 0.327), respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9: Comparison of the abundances of the different bacteria across the BV states in the urine 
and swab samples.  
4.3.3 Comparison of the abundance of each bacterium in BV negative and BV positive samples  
G. vaginalis was observed as the most abundant microorganism, followed by A. vaginae and P. bivia 
in the BV positive women, whereas L. crispatus was the most abundant in the BV negative women. A 
higher abundance of A. vaginae and G. vaginalis was observed in BV positive when compared to BV 
negative women as expected. This association was found to be statistically significant (p<0.001). 
However, there was no statistically significant association between the abundance of P. bivia across the 
BV states (p=0.228). As expected, a higher abundance of L. crispatus was shown to be present in the 
BV negative samples when compared to the BV positive samples (p= 0.002) (Fig. 10).  
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Fig. 10: The abundance of each bacterium in relation to BV status 
 
4.3.4. Comparison of bacterial abundance related to clinical symptoms of discharge  
The median copy numbers of the individual bacteria was compared to the clinical symptom of 
discharge. A higher abundance of G. vaginalis was observed in women who presented with abnormal 
vaginal discharge when compared to women who reported not having any discharge.  This association 
was found to have a borderline significance (p=0.062). Similarly, a higher abundance of P. bivia was 
observed in women with discharge (p=0.032). There was no significant association between clinical 
symptoms and A. vaginae and L. crispatus (p>0.05) (Fig. 11).  
p < 0.001
p = 0.002
p = 0.228
p < 0.001
P.Bivia
L.Crispatus
G.Vaginalis
A.Vaginae
0 3000 6000 9000
Abundance
P
a
th
o
g
e
n
Status: Negative Positive
23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11: Comparison of bacterial abundances in relation to abnormal vaginal discharge in swab 
samples.  
4.3.5. Comparison of bacterial abundance related to trimester of pregnancy   
According to Fig. 12, there is no significant association between the abundance of A. vaginae, G. 
vaginalis and P. bivia in women across the different trimesters of pregnancy (p>0.05) (Fig. 12). 
However, a higher abundance of L. crispatus was observed in women in the third trimester of pregnancy 
when compared to women in the first and second trimester of pregnancy. This association was found to 
be statistically significant (p= 0.021).  
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Fig. 12: Abundance of the individual bacteria across the different trimesters of pregnancy 
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CHAPTER FIVE 
5. DISCUSSION  
Bacterial vaginosis is a clinical condition that is classically diagnosed using a vaginal swab. Nugent 
Scoring is performed to detect if a patient is BV positive, intermediate or negative (15, 45). However, 
science is moving towards molecular techniques to detect BV since molecular techniques are able to 
detect the BV-associated pathogens more accurately (5, 14, 18, 33). BV plays a negative role in pregnant 
women as it may result in severe consequences to the unborn infant. The collection of vaginal swabs to 
detect pathogens during pregnancy is not practical and is extremely uncomfortable for the mother. Urine 
may be considered as an ideal sample choice for the detection of pathogens (especially from pregnant 
women) since it is non-invasive and easy to collect.  
This study provides the first evidence for the detection and quantification of BV-associated bacteria (G. 
vaginalis, P. bivia, A. vaginae and L. crispatus) in urine samples collected from South African pregnant 
women.  In addition, this study provides the first report on the use of droplet digital PCR (ddPCR) for 
the detection and quantification of these specific bacteria.  
The present study employed the use of a high-throughput ddPCR system to determine the absolute 
quantification of DNA copy numbers without the need to generate a standard curve. This technology 
has been reported to provide higher precision and sensitivity than real-time PCR and is less labour 
intensive (40, 41). To date, ddPCR has been used for the quantitative detection of numerous pathogens 
(46-49). Currently, there is a lack of data on the use of ddPCR for quantification of BV-associated 
pathogens. This study was able to successfully use ddPCR to detect these BV-associated pathogens in 
both urine and vaginal swab samples regardless of the purity of the DNA. Thereby, making ddPCR a 
reliable technology to detect BV-associated pathogens. Droplet digital PCR was able to successfully 
detect and quantify G. vaginalis, A. vaginae, P. bivia and L. crispatus across the BV states (BV negative 
and positive) from urine and vaginal swab DNA samples. As expected, a higher copy of G. vaginalis, 
A. vaginae and P. bivia was present in the BV positive samples when compared to BV negative samples.  
This study showed G. vaginalis to be the most abundant BV microorganism when compared to A. 
vaginae and P. bivia in the samples tested. This correlates with previous study findings that have 
reported Gardnerella to be the leading BV-associated pathogen (3, 26, 32, 50). The levels of abundance 
of G. vaginalis is used as the indicative microorganism for BV (32). In a study conducted by Beverly 
et al (2005), the results demonstrated that quantitative PCR for G. vaginalis, significantly correlates 
with the Nugent Gram stain method for BV diagnosis (51).  It was found that women who were 
diagnosed as BV positive according to the Nugent score, had significantly higher numbers of G. 
vaginalis (p< 0.0001) in the cervicovaginal lavage (CVL) when compared to women without BV (51). 
Similarly, in the current study, a high load of G .vaginalis was detected in all the BV positive samples 
(both urine and vaginal swabs). This result was expected as G. vaginalis is one of the key BV 
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microorganisms that is searched for when performing Nugent scoring (15, 32, 51). If there is sufficient 
quantity of G. vaginalis present in the vaginal smear, the patient is diagnosed as BV positive in the 
Nugent scoring method (15).  
The findings from the present study indicated that urine is an appropriate sample for detection of G. 
vaginalis since a good correlation was obtained between urine and swabs (R=0.63, p<0.0001).  The 
findings of this study are supported by other studies conducted internationally. In a study conducted by 
Swidsinski et al (2013), the authors reported on the presence of G. vaginalis in first-void urine samples 
obtained from German pregnant women (31). More recently, Datcu et al (2014) also demonstrated the 
potential to detect G. vaginalis from a urine sample collected from women in the general population of 
Greenland (45).   
In this study, A. vaginae was the second most abundant bacterium detected amongst the BV-associated 
pathogens. This was expected as Atopobium species have been discovered to be found in the vaginal 
microbiota of women with BV (52). A study conducted by Bradshaw et al (2006) also reported on the 
presence of A. vaginae in Australian women diagnosed with BV in Melbourne, Australia (33). The 
current study found that there was a significant difference of A. vaginae in the swab sample compared 
to the urine sample and a poor correlation (R=0.21, p=0.001) between both sample types was noted.  
Prevotella was reported as the least abundant amongst the other two pathogens in this study. Machado 
et al (2015) noted that a symbiotic relationship between G. vaginalis and P. bivia exists (5). This 
demonstrates that the presence of a G. vaginalis biofilm stimulates the growth of P. bivia in vitro (5), 
thereby, explaining the reason for the lower mean concentration of P. bivia when compared to the other 
investigative pathogens.  
The current study found a strong correlation (R=0.50, p= <0.0001) between the urine and swabs samples 
for the detection of P. bivia. Similar results were found in a study conducted by Datcu et al (2014) in 
women from the general population of Greenland, thereby confirming our findings on the detection of 
Prevotella from urine (45). After an extensive survey of the literature, there were no published findings 
on the detection of A. vaginae and P. bivia from urine samples collected from pregnant women, thereby 
limiting the discussion of the current study. However, the current study now provides data that fills this 
gap in knowledge.  
According to the ddPCR analysis, L. crispatus was shown to be present at a higher abundance in the 
BV negative samples when compared to the BV positive samples. This result was expected as L. 
crispatus is associated with the healthy vaginal microbiota (2, 37, 53). In this study, L. crispatus was 
shown to be present in both urine and swabs samples from women who were classified as BV negative. 
A good correlation between the two sample types was observed (R= 0.71, p<0.0001). The result 
correlates with literature as L. crispatus is associated with BV negative diagnosis. L. crispatus produces 
lactic acid and other compounds that are inhibitors of BV-associated bacterial species. Women 
27 
 
colonized by L. crispatus in their vagina, are less likely to develop BV (37, 53). Obtaining data on 
bacteria that are positively and negatively associated with BV will assist with future studies that aim to 
determine the bacterial load cut-off in urine for optimal BV prediction. This provides the rationale for 
the inclusion of L. crispatus in the current study.  
To date, published studies that have reported on the detection of BV-associated bacteria from urine have 
performed labour intensive molecular assays such as fluorescent in situ hybridization (FISH) and 
conventional real-time PCR (requiring the generation of a standard curve) (31, 45). The current study 
has the strength in that it employed the use of a high-throughput ddPCR system to determine absolute 
quantification of DNA copy numbers without the need to generate a standard curve. This technology 
has been reported to provide higher precision and sensitivity than real-time PCR assays and is less 
labour intensive (40, 41).  
The results obtained in this study indicate the successful detection and quantification of all investigative 
BV-associated bacteria from urine samples using ddPCR. The detection of BV-associated pathogens 
from urine offers a much more comfortable and less biased sampling method when compared to self-
collected vaginal swabs (downstream processing is dependent on amount of material on swab). 
Moreover, ddPCR was able detect the bacteria in urine that was collected at any-time (study did not 
request first-void urine only) thereby indicating the potential of ddPCR to detect exact copy numbers 
regardless of when the urine was collected. Droplet digital PCR was able to detect these BV-associated 
pathogens regardless of the purity of the DNA. The lack of published data on the detection of BV 
pathogens from urine samples collected from pregnant women in the South African and the African 
setting lends novelty to the present study.  In addition, there is currently no published work on the use 
of ddPCR for absolute quantification of BV-associated microorganisms.  
The present study had the following limitations: firstly every known vaginal bacterium known to cause 
BV was not attempted to be investigated (bacterial vaginosis-associated bacterium 2, Eggerthella-like 
bacterium, Sneathia, Megasphaera type 1, Mobiluncus) due to funding restraints, and lastly, the present 
study was a sub-study which only included 100 patient samples.  
However, the strengths of this study are as follows, the stratification according to BV status was 
performed using an FDA approved automated assay for the detection of BV (i.e. BD MAX vaginal 
panel assay), which is highly sensitive, specific and is not subjective. As mentioned previously, the 
current study used ddPCR which is highly sensitive to determine absolute quantification of DNA copy 
number without the need to generate a standard curve. This assay has been reported to be a more 
sensitive method than real-time PCR and is less labour intensive. In addition, ddPCR can be used to 
detect and quantify target sequences with DNA that has been degraded and contain inhibitory 
substances.  The data obtained from this study can be used as preliminary data to develop larger studies 
on this technology.  
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CHAPTER SIX 
6. CONCLUSION  
Bacterial vaginosis (BV) affects approximately 42.1% of young South African women between the ages 
of 15-24 years. (54). The prevalence of BV in South African pregnant women is approximately 17.6% 
(21) and in Durban, the prevalence of BV in women  is 52% (1). For pregnant women, BV results in 
late miscarriages, preterm labour, premature rupture of membranes (PROM), post-partum endometritis, 
low birth weight infants and a host of other complications (6, 13, 14). The preferred method for 
diagnosis of BV is nucleic acid amplification as it results in more accurate detection and diagnosis.  The 
current nucleic acid methods that is used for detection of BV is the FDA approved BD MAX Vaginal 
panel assay and conventional real-time PCR. However, the disadvantages of using these platforms is 
that it only uses vaginal swabs for detection, the platforms are relatively expensive and are dependent 
on the sample integrity which means that if  there is less material on the vaginal swab the platforms will 
be unable to detect the pathogens. Whereas, ddPCR, provides absolute quantification without the need 
of a standard curve, the amplification is not affected by sample inhibitors or poor amplification 
efficiency and the technology is able to detect low-copy number variants. Furthermore, ddPCR is cost 
effective, uses lower sample and reagent volumes compared to other molecular methods whilst still 
maintaining the overall sensitivity and precision. In this study, ddPCR was also able to detect the BV 
associated pathogens from low concentration and low purity DNA samples. 
Droplet digital PCR proves more advantageous, as it was able to successfully detect the pathogenic BV-
causing investigative microorganisms from urine DNA samples in this study. The use of urine as an 
alternative method of sample collection as opposed to vaginal swab samples is highly favoured as it is 
less invasive and provides easy collection. In majority of the health care clinical settings, pregnant 
women are screened for glucose and leukocyctes in urine (45). Therefore, urine is already collected 
which makes urine easy to be collected for BV testing.  Thus, the use of urine as an alternative sample 
collection method is more feasible. Collecting a vaginal swab from pregnant women who are at an 
advanced gestation age can be extremely uncomfortable and causes discomfort. Urine samples can be 
easily collected without any discomfort experienced.  
In this study, a positive correlation was detected between urine and vaginal swab samples for all 
investigative BV-associated pathogens thereby indicating that urine can successfully be used as an 
alternative method to diagnose BV. Similarly, a study conducted by  Datcu et al (2014) showed a linear 
correlation between vaginal and urine samples (17). The study further demonstrated that as a result of 
the linear correlation it can be assumed that the bacterial DNA loads quantified in the urine sample 
possibly represents vaginal secretions washed out by the urine rather than presence of bacterial 
associated with UTIs (17). Similarly, this assumption could be applied to the present study findings 
observed with the urine samples. This further emphasizes the validity of possibly using urine as an 
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alternative sample collection method as opposed to vaginal swabs. A future research direction will be 
to develop ddPCR using urine as a diagnostic test for BV.  
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CHAPTER EIGHT 
8. APPENDICES 
APPENDIX 1: Raw data from the ddPCR results and DNA extraction as well as the Schematic of 
ddPCR controls for selected microorganism 
 
Correlation between sample numbers sent for ddPCR and participant ID numbers. 
BV Negative BV Positive 
Sample 
Number 
Sample number on vaginitis 
study 
Sample 
Number 
Sample number on vaginitis 
study 
S1 V29 S26 V35 
S2 V30 S27 V42 
S3 V33 S28 V44 
S4 V39 S29 V124 
S5 V40 S30 V47 
S6 V43 S31 V50 
S7 V49 S32 V51 
S8 V56 S33 V53 
S9 V63 S34 V55 
S10 V65 S35 V57 
S11 V70 S36 V74 
S12 V71 S37 V76 
S13 V72 S38 V81 
S14 V75 S39 V009 
S15 V78 S40 V010 
S16 V79 S41 V011 
S17 V82 S42 V013 
S18 V85 S43 V017 
S19 V86 S44 V018 
S20 V89 S45 V019 
S21 V93 S46 V024 
S22 V95 S47 V001 
S23 V96 S48 V003 
S24 V101 S49 V027 
S25 V102 S50 V083 
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Table showing the DNA purity and DNA concentration values for urine and swab samples  
 
Sample  ID Sample type (Urine/ Swabs) BV status Purity (A260/A280) Concentration (ng/µl) 
V001 Swab BV 
positive 
1.65 36.8 
V003 Swab BV 
positive 
1.72 7.2 
V009 Swab BV 
positive 
1.75 26.2 
V010 Swab BV 
positive 
1.87 134.6 
V011 Swab BV 
positive 
1.07 8.5 
V013 Swab BV 
positive 
1.68 5.7 
V017 Swab BV 
positive 
1.46 6.2 
V018 Swab BV 
positive 
1.77 14.5 
V019 Swab BV 
positive 
1.65 7.1 
V024 Swab BV 
positive 
1.82 53.8 
V027 Swab BV 
positive 
1.58 17.6 
V035 Swab BV 
positive 
1.20 14.8 
V042 Swab BV 
positive 
1.84 38.7 
V044 Swab BV 
positive 
0.88 3.5 
V047 Swab BV 
positive 
1.82 16.0 
V050 Swab BV 
positive 
1.05 3.5 
V051 Swab BV 
Positive 
1.68 37.4 
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V055 Swab BV 
positive 
1.84 9.3 
V057 Swab BV 
positive 
1.63 4.3 
V074 Swab BV 
positive 
1.84 24.5 
V076 Swab BV 
positive 
1.76 8.8 
V081 Swab BV 
positive 
1.62 7.0 
V083 Swab BV 
positive 
1.81 30.9 
V124 Swab BV 
positive 
1.83 7.6 
V053 Swab BV 
positive 
1.87 11.8 
V029 Swab BV 
negative 
1.71 16.4 
V030 Swab BV 
negative 
1.55 7.8 
V033 Swab BV 
negative 
1.72 6.9 
V039 Swab BV 
negative 
1.80 13.3 
V040 Swab BV 
negative 
1.45 4.9 
V043 Swab BV 
negative 
1.46 7.3 
V049 Swab BV 
negative 
1.77 4.9 
V056 Swab BV 
negative 
1.87 23.4 
V063 Swab BV 
negative 
1.81 13.9 
V065 Swab BV 
negative 
1.81 29.9 
V070 Swab BV 
negative 
1.56 16.3 
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V071 Swab BV 
negative 
1.35 3.2 
V072 Swab BV 
negative 
1.82 76.4 
V075 Swab BV 
negative 
1.84 12.6 
V078 Swab BV 
negative 
1.83 21.3 
V079 Swab BV 
negative 
1.29 17.6 
V082 Swab BV 
negative 
1.54 2.6 
V085 Swab BV 
negative 
1.26 21.2 
V086 Swab BV 
negative 
1.87 19.4 
V089 Swab BV 
negative 
1.78 16.1 
V093 Swab BV 
negative 
1.72 10.5 
V095 Swab BV 
negative 
1.47 10.8 
V096 Swab BV 
negative 
1.61 6.0 
V101 Swab BV 
negative 
1.11 63.6 
V102 Swab BV 
negative 
1.35 3.6 
V001 Urine BV 
positive 
0.88 17.9 
V003 Urine BV 
positive 
1.08 3.0 
V009 Urine BV 
positive 
0.32 7.3 
V010 Urine BV 
positive 
0.41 1.7 
V011 Urine BV 
positive 
0.32 585.0 
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V013 Urine BV 
positive 
0.40 162.3 
V017 Urine BV 
positive 
1.84 19.2 
V018 Urine BV 
positive 
1.17 2.1 
V019 Urine BV 
positive 
1.90 15.4 
V024 Urine BV 
positive 
1.25 1.2 
V027 Urine BV 
positive 
1.97 6.0 
V035 Urine BV 
positive 
0.85 4.8 
V042 Urine BV 
positive 
0.99 13.9 
V044 Urine BV 
positive 
1.45 10.5 
V047 Urine BV 
positive 
1.78 10.2 
V050 Urine BV 
positive 
0.43 6.9 
V051 Urine BV 
Positive 
0.42 9.9 
V055 Urine BV 
positive 
0.72 31.8 
V057 Urine BV 
positive 
0.94 5.2 
V074 Urine BV 
positive 
1.49 15.5 
V076 Urine BV 
positive 
0.41 461.2 
V081 Urine BV 
positive 
0.37 4.9 
V083 Urine BV 
positive 
1.27 6.1 
V124 Urine BV 
positive 
1.51 4.2 
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V053 Urine BV 
positive 
1.55 14.2 
V029 Urine BV 
negative 
1.57 14.2 
V030 Urine BV 
negative 
0.66 5.1 
V033 Urine BV 
negative 
0.33 520.7 
V039 Urine BV 
negative 
1.24 5.5 
V040 Urine BV 
negative 
1.16 81.2 
V043 Urine BV 
negative 
0.36 10.5 
V049 Urine BV 
negative 
0.77 28.9 
V056 Urine BV 
negative 
1.48 81.0 
V063 Urine BV 
negative 
0.42 4.9 
V065 Urine BV 
negative 
0.88 1.9 
V070 Urine BV 
negative 
0.76 11.9 
V071 Urine BV 
negative 
1.41 5.2 
V072 Urine BV 
negative 
1.53 24.9 
V075 Urine BV 
negative 
0.32 4.7 
V078 Urine BV 
negative 
1.82 12.6 
V079 Urine BV 
negative 
1.83 12.6 
V082 Urine BV 
negative 
1.05 3.1 
V085 Urine BV 
negative 
1.11 3.9 
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V086 Urine BV 
negative 
1.93 3.5 
V089 Urine BV 
negative 
1.09 8.8 
V093 Urine BV 
negative 
1.44 4.0 
V095 Urine BV 
negative 
1.44 11.4 
V096 Urine BV 
negative 
26.6 1.65 
V101 Urine BV 
negative 
1.29 6.0 
V102 Urine BV 
negative 
1.22 31.1 
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Schematic of ddPCR controls for selected microorganism 
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APPENDX 2: Supporting documents 
Includes informed consent form, enrollment form, initial BREC approval letter and BREC 
amendments approval letter 
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